|  |
| --- |
| **SWGLH – Cancer Genomics Test Request Form****Solid Tumour and Lymphoid Pathology – Sarcoma**Please complete electronically: type or click in the grey boxes, send this request to the appropriate Histopathology laboratory as soon as possible |

|  |
| --- |
| **Patient Details**: Paste patient demographics here or fill in fields below: |

|  |  |
| --- | --- |
| Patient name:       | Referring Consultant:       |
| Address:          Postcode:       | Department and Hospital:       |
| Report destination (nhs.net e-mail/s):           |
| DOB:       | Sex:       | Pathologist:       |
| NHS number:       | Date of resection/biopsy:       |
| Pathology block number:       | Date test requested:        |
| Hospital number:       | Date sample sent to SW GLH:       |

|  |
| --- |
| **Clinical summary:**       |
|  |
| **Whole genome sequencing for germline and tumour is available for sarcoma, please refer to the following link for requesting details:**[**https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub/swglh-sample-test-information/swglh-whole-genome-sequencing-service**](https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub/swglh-sample-test-information/swglh-whole-genome-sequencing-service)**For the full sarcoma test directory refer to the National Genomics Test Directory (NGTD) for Cancer**: [**https://www.england.nhs.uk/publication/national-genomic-test-directories/**](https://www.england.nhs.uk/publication/national-genomic-test-directories/)**.** If testing is not present as an option on this referral form, please email the laboratory directly at **SWGLHcancer@nbt.nhs.uk** prior to sending samples. Please note some tests will be exported to other genomic laboratory hubs for testing.**If the M code is not detailed below, please specify in ‘Other test’ box.** |
| **RNA gene panel** **Below is a list of all genes present on this panel. Please note, all the genes listed will be analysed\*.***AGK, AKAP9, AKT3, ALK, AR, ASPSCR1, AXL, BCL9, BCOR, BRAF, BRCA1, BRCA2, BRD2, BRD3, BRD4, CAMTA1, CCDC6, CCNB3, CDK4, CIC, COL1A1, CPNE1, CPSF6, CTNNB1, DDIT3, DNAJB1, EGFR, ELM4, EPC1, ERBB2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, FAM118B, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1, FMR1, FN1, FOSB, FOXO1, FUS, FXR1, GNA11, HEY1, HNRNPH1, IDH1, IDH2, JAZF1, KDR, KIAA1549, KIT, LGR5, MACF1, MALAT1, MAML2, MET, MITF, MN1, MSH2, MYB, MYBL1, MYC, NAB2, NCOA2, NFIA, NFIB, NOTCH1, NOTCH2, NOTCH3, NPM1, NR4A3, NRG1, NTRK1, NTRK2, NTRK3, NUP107, NUTM1, NUTM2B, NUTM2E, OGA, PAX3, PAX7, PDGFB, PDGFRA, PDGFRB, PHF1, PIK3CA, PLAG1, PPARG, PRCC, PRKACA, PTPRK, PVT1, RAF1, RARG, RELA, RET, ROS1, RPS6KB1, RSPO3, SERPINE1, SRGAP3, SS18, STAT6, SUZ12, TCL1B, TFE3, TFEB, TGFBR3, TMP3, TMPRSS2, TPM4, TTYH1, USP6, WT1, WWTR1, YAP1, YWHAE, ZFTA.* |
|

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Code** | **Clinical Indication** |  | **Code** | **Clinical Indication** |  |
| M42.5 | Alveolar Rhabdomyosarcoma | [ ]  | M72.1 | Primitive Mesenchymal Myxoid | [ ]  |
| M43.3 | Alveolar Soft Part Sarcoma | [ ]  | M74.3 | Radiation Induced Angiosarcoma | [ ]  |
| M45.4 | Angiomatoid Fibrous Histiocytoma | [ ]  | M75.1 | Round cell Sarcoma NOS | [ ]  |
| M45.4 | Angiomatoid Fibrous Histiocytoma | [ ]  | M76.3 | Sclerosing Epithelioid Fibrosarcoma | [ ]  |
| M48.3 | Clear Cell Sarcoma of Soft Tissue | [ ]  | M77.3 | Synovial Sarcoma | [ ]  |
| M49.1 | CNS Ewing Sarcoma Family tumour with CIC alteration | [ ]  | M78.1 | Undifferentiated Round Cell Sarcoma of Infancy | [ ]  |
| M50.3 | Dermatofibrosarcoma Protuberans | [ ]  | M79.3 | Well Differentiated/Dedifferentiated Liposarcoma | [ ]  |
| M52.1 | Desmoplastic Small Round Cell Tumour | [ ]  | M197.1 | Round Cell Sarcoma of Soft Tissue Differential | [ ]  |
| M54.2 | Epithelioid Haemangioendothelioma | [ ]  | M198.5 | Vascular Soft Tissue Tumour Differential | [ ]  |
| M55.1 | Ewing Like Sarcoma/PNET | [ ]  | M199.2 | Spindle Cell Soft Tissue Tumour Differential | [ ]  |
| M57.1 | Ewing Like Soft-Tissue Sarcoma | [ ]  | M200.1 | Myxoid Soft Tissue Tumour Differential | [ ]  |
| M58.3 | Extraskeletal Myxoid Chondrosarcoma | [ ]  | M201.4 | Adipocytic Soft Tissue Tumour Differential | [ ]  |
| M61.1 | High-Grade Neuroepithelial Tumour- Bcor Group | [ ]  | M202.7 | Epithelioid Soft Tissue Tumour Differential | [ ]  |
| M64.3 | Low Grade Fibromyxoid Sarcoma | [ ]  | M203.6 | Uterine Sarcomas (Inc Endometrial) | [ ]  |
| M66.3 | Myoepithelial Tumours of Soft Tissue | [ ]  | M204.2  | Undifferentiated tumour | [ ]  |
| M67.3 | Myxoid/Round Cell Liposarcoma | [ ]  | M227.1 | NTRK fusion analysis (*NTRK1, NTRK2, NTRK3*) | [ ]  |
| M71.3 | Phosphaturic Mesenchymal Tumour | [ ]  |  | **Other test** [ ]  Specify:       | [ ]  |

\*Please note that some of these genes are also available as a FISH request. Please refer to the NGTD or contact the laboratory to determine availability. If this is required please complete the ‘other test’ option under the FISH request section

|  |
| --- |
| **DNA gene panel** Please select based on the gene being tested or clinical details.  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Code** | **Clinical indication** | **Test code** | **Test name** |  |
| M51 | Desmoid-Type Fibromatosis | M51.1 | Multi-target NGS panel - small variant (APC, CTNNB1) | [ ]  |
| M59 | Fibrous Dysplasia/Myxomas (Mazabraud Syndrome) | M59.1 | Multi-target NGS panel - small variant (GNAS) | [ ]  |
| M199 | Spindle Cell Soft Tissue Tumour Differential | M199.1 | Multi-target NGS panel - small variant (APC, CTNNB1) | [ ]  |
|  |  |  | **Other test** [ ]  Specify:       |  |

|  |
| --- |
| **FISH**  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Code** | **Clinical Indication** | **Test code** | **Test Name** |  |
| M79 | WellDifferentiated/Dedifferentiated Liposarcoma | M79.1 | *MDM2* copy number FISH | [ ]  |
| M199 | Spindle Cell Soft Tissue Tumour Differential | M199.5 | *MDM2* copy number FISH | [ ]  |
| M201 | Adipocytic Soft Tissue Tumour Differential | M201.2 | *MDM2* copy number FISH | [ ]  |
|  |  |  | **Other test** [ ]  |  |

**\*Sample Requirements:****Tumour DNA and/or RNA extraction**[ ]  Sample with >**20%** neoplastic cells: send one tube (Eppendorf or Universal): containing 5 x 10µm sections (curls/scrolls) OR[ ]  Sample with **<20%** neoplastic cells: send 10 x 5µm slide mounted sections along with H&E with region/s of >20% neoplastic cells circled to enable macro-dissection and extraction of sample with >20% neoplastic cellsNB. If two tests are required the same requirements apply, i.e. it is not necessary to send double the material.**Please indicate the percentage neoplastic cell content in the curls or the marked region of the H&E:**[ ]  <20% (not recommended due to risk of false negative result but please specify reason and neoplastic cell content if sending       )[ ]  20-30% [ ]  31-40% [ ]  41-50% [ ]  51-60% [ ]  61-70% [ ]  71-80% [ ]  81-90% [ ]  91-100%**FISH**[ ]  Please send 2 x 4µm and 2 x 2µm sections on 'APES' or 'sticky' slides **per test** required with an accompanying H&E slide with the appropriate tumour rich area(s) marked.Please note that we are unable to receive blocks and require cut material to be sent as stipulated above.Please label **all** slides or tubes with three patient identifiers i.e. name, block number and date of birth. |
| **Samples should be dispatched as soon as possible as the patient’s treatment may be dependent upon the molecular analysis.****Send paperwork and sample to:** Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Bristol BS10 5NB**Phone:** 0117 414 6168 **Email:** **SWGLHcancer@nbt.nhs.uk*****CONSENT STATEMENT It is the referring clinician’s responsibility to ensure that the patient/carer knows the purpose of the test and that the DNA sample will be retained in long term storage and may be used for future diagnostic tests. Completing this form is an indication that the clinician has obtained consent for testing and storage. The patient should be advised that the sample may be used anonymously for quality assurance and training purposes. Please advise us of any restrictions.***  |